title: Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma.
authors: Yasuhiro
authors: Y
authors: Oki
authors: Amanda
authors: A
authors: Copeland
authors: Jorge
authors: J
authors: Romaguera
authors: Luis
authors: L
authors: Fayad
authors: Michelle
authors: M
authors: Fanale
authors: Silvana de Castro
authors: Sde C
authors: Faria
authors: L Jeffrey
authors: LJ
authors: Medeiros
authors: Percy
authors: P
authors: Ivy
authors: Anas
authors: A
authors: Younes
mesh_terms: D000328:Adult; D000368:Aged; D016227:Benzoquinones / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors*; D006801:Humans; D047029:Lactams, Macrocyclic / Q000627:therapeutic use*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D016227:Benzoquinones; D018841:HSP90 Heat-Shock Proteins; D047029:Lactams, Macrocyclic; C112765:tanespimycin